New transplant method aims to reduce dangerous immune reactions
NCT ID NCT03192397
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the patient's body. The trial includes 35 participants and aims to see if this combination reduces severe long-term complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide
- What this could lead to
- If successful, this approach could lower the risk of graft-versus-host disease, making stem cell transplants safer and more effective for blood cancer patients.
- What could go wrong
- This is an early-phase trial with only 35 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and radiation, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?